magazinelogo

International Journal of Clinical and Experimental Medicine Research

ISSN Online: 2575-7970 ISSN Print: 2575-7989 CODEN: IJCEMH
Frequency: bimonthly Email: ijcemr@hillpublisher.com
Total View: 2455281 Downloads: 551402 Citations: 244 (From Dimensions)
ArticleOpen Access http://dx.doi.org/10.26855/ijcemr.2023.07.008

Remnant Cholesterol and Atherosclerotic Disease: A Mini Review of Literature

Cui Chen1, Tao Tang1, Mao Liu2,*

1Laboratory of Genetics, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.

2Department of Cardiology, Cardiovascular Research Center, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.

*Corresponding author: Mao Liu

Published: August 10,2023

Abstract

Atherosclerotic diseases such as coronary heart disease, ischemic stroke and peripheral artery stenosis have become the major public health problems in the world. Remnant cholesterol (RC) is the cholesterol content of all triglyceride rich lipoproteins. At present, it has been found that one third of the total cholesterol in plasma is RC, which is considered to be the main atherosclerosis agent that causes the formation of foam cells and plaque in the arterial wall. RC can lead to endothelial dysfunction, which in turn affects the regulation of hemostatic mechanisms caused by reduced concentrations of tissue-factor pathway inhibitor and thrombomodulin. Besides, elevated RC is causally associated with low-grade inflammation and plays an important role in the process of atherosclerotic disease. Growing evidence has supported a causal role for RC in coronary heart disease and ischemic stroke. This mini review, focusing on the definition, metabolism, measurement and atherogenicity of RC, aims to give an integrative introduction of RC and summarize the relationship between elevated RC and atherosclerotic diseases.

Keywords

Remnant cholesterol, atherosclerosis, coronary heart disease, ischemic stroke, review

References

[1] Fan J, Watanabe T. Atherosclerosis: Known and unknown [J]. Pathol Int, 2022, 72(3):151-160.

[2] Writing Committee of the Report. Key points of Report on Cardiovascular Health and Diseases in China 2020 [J]. Chinese Journal of Cardiovascular Research, 2021, 19(7):582-590.

[3] Report Group of Stroke Prevention. Brief report on stroke prevention and treatment in China 2020 [J]. Chinese Journal of Cerebrovascular Diseases, 2022, 19(2):136-144.

[4] Wang K, Wang R, Yang J, et al. Remnant cholesterol and atherosclerotic cardiovascular disease: Metabolism, mechanism, evidence, and treatment [J]. Front Cardiovasc Med, 2022, 9:913869.

[5] Zhang K, Qi X, Zhu F, et al. Remnant cholesterol is associated with cardiovascular mortality [J]. Front Cardiovasc Med, 2022, 9:984711.

[6] Masuda D, Yamashita S. Postprandial Hyperlipidemia and Remnant Lipoproteins [J]. J Atheroscler Thromb, 2017, 24(2): 95-109.

[7] Esan O, Wierzbicki A S. Triglycerides and cardiovascular disease [J]. Curr Opin Cardiol, 2021, 36(4):469-477.

[8] Burnett J R, Hooper A J, Hegele R A. Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk [J]. J Am Coll Cardiol, 2020, 76(23):2736-2739.

[9] Nordestgaard B G, Varbo A. Triglycerides and cardiovascular disease [J]. Lancet, 2014, 384(9943):626-635.

[10] Sandesara P B, Virani S Sande Sara, Fazio S, et al. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk [J]. Endocr Rev, 2019, 40(2):537-557.

[11] Varbo A, Nordestgaard B G. Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction [J]. Eur Heart J, 2021, 42(47):4833-4843.

[12] Lupton J R, Faridi K F, Martin S Farida, et al. Deficient serum 25-hydroxyvitamin D is associated with an atherogenic lipid  profile: The Very Large Database of Lipids (VLDL-3) study [J]. J Clin Lipidol, 2016, 10(1):72-81.

[13] Rosenson R S, Davidson M H, Hirsh B J, et al. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease [J]. J Am Coll Cardiol, 2014, 64(23):2525-2540.

[14] Miller Y I, Choi S H, Fang L, et al. Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis [J]. Subcell Biochem, 2010, 51:229-251.

[15] Langsted A, Madsen C M, Nordestgaard B G. Contribution of remnant cholesterol to cardiovascular risk [J]. J Intern Med, 2020, 288(1):116-127.

[16] Alipour A, van Oostrom A J, Izraeljan A, et al. Leukocyte activation by triglyceride-rich lipoproteins [J]. Arterioscler Thromb Vasc Biol, 2008, 28(4):792-797.

[17] Ting H J, Stice J P, Schaff U Y, et al. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha [J]. Circ Res, 2007, 100(3):381-390.

[18] Varbo A, Benn M, Nordestgaard B G. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment [J]. Pharmacol Ther, 2014, 141(3):358-367.

[19] Saeed A, Feofanova E V, Yu B, et al. Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease [J]. J Am Coll Cardiol, 2018, 72(2):156-169.

[20] Hoogeveen R C, Ballantyne C M. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein (a), and Inflammation [J]. Clin Chem, 2021, 67(1):143-153.

[21] Varbo A, Benn M, Tybjaerg-Hansen A, et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation [J]. Circulation, 2013, 128(12):1298-1309.

[22] Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma [J]. Clin Chim Acta, 2006, 367(1-2):36-47.

[23] Weitz J I, Fazio S. Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis [J]. Circ Res, 2019, 124(3):351-353.

[24] Ma H, Aziz K S, Huang R, et al. Arterial wall cholesterol content is a predictor of development and severity of arterial thrombosis [J]. J Thromb Thrombolysis, 2006, 22(1):5-11.

[25] Spasic I, Ubavic M, Sumarac Z, et al. Influence of lipid metabolism disorders on venous thrombosis risk [J]. J Med Biochem, 2021, 40(3):245-251.

[26] Trub A G, Wagner G R, Anderson K A, et al. Statin therapy inhibits fatty acid synthase via dynamic protein modifications [J]. Nat Commun, 2022, 13(1):2542.

[27] Ohmura H. Contribution of Remnant Cholesterol to Coronary Atherosclerosis [J]. J Atheroscler Thromb, 2022, 29(12):1706-1708.

[28] Castaner O, Pinto X, Subirana I, et al. Remnant Cholesterol, Not LDL Cholesterol, Is Associated with Incident Cardiovascular Disease [J]. J Am Coll Cardiol, 2020, 76(23):2712-2724.

[29] Do R, Willer C J, Schmidt E M, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease [J]. Nat Genet, 2013, 45(11):1345-1352.

[30] Varbo A, Nordestgaard B G. Remnant Cholesterol and Triglyceride-Rich Lipoproteins in Atherosclerosis Progression and Car-diovascular Disease [J]. Arterioscler Thromb Vasc Biol, 2016, 36(11):2133-2135.

[31] Elshazly M B, Mani P, Nissen S, et al. Remnant cholesterol, coronary atheroma progression and clinical events instatin-treated patients with coronary artery disease [J]. Eur J Prev Cardiol, 2020, 27(10):1091-1100.

[32] Levin M G. Remnant Lipoproteins as a Target for Atherosclerosis Risk Reduction [J]. Arterioscler Thromb Vasc Biol, 2021, 41(6):2076-2079.

[33] Kim J Y, Park J H, Jeong S W, et al. High levels of remnant lipoprotein cholesterol is a risk factor for large artery atherosclerotic stroke [J]. J Clin Neurol, 2011, 7(4):203-209.

[34] Varbo A, Nordestgaard B G. Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population [J]. Ann Neurol, 2019, 85(4):550-559.

[35] Li W, Huang Z, Fang W, et al. Remnant Cholesterol Variability and Incident Ischemic Stroke in the General Population [J]. Stroke, 2022, 53(6):1934-1941.

How to cite this paper

Remnant Cholesterol and Atherosclerotic Disease: A Mini Review of Literature

How to cite this paper:  Cui Chen, Tao Tang, Mao Liu. (2023) Remnant Cholesterol and Atherosclerotic Disease: A Mini Review of Literature. International Journal of Clinical and Experimental Medicine Research7(3), 339-343.

DOI: http://dx.doi.org/10.26855/ijcemr.2023.07.008